HEPATOCELLULAR CARCINOMA (HCC)

This study investigates whether regular blood tests can detect liver cancer earlier in people with type 2 diabetes who also have significant liver scarring. Participants are randomly assigned to either a surveillance group receiving specialized blood tests every six months or a s…

This study tests a radiation treatment called SIRT (selective internal radiation therapy) using tiny radioactive beads delivered directly to liver tumors. The goal is to shrink tumors enough so that patients with liver cancer can qualify for a liver transplant or have surgery to …

This study tests a new planning method called multicompartment dosimetry (MCD) for TheraSphere, a treatment that delivers tiny radioactive beads to liver tumors. The goal is to give a higher radiation dose to the tumor while protecting healthy liver. Researchers will enroll 140 p…

This study tests an experimental oral drug called VMD-102 in people with advanced solid tumors, including liver, lung, kidney, skin (uveal melanoma), and colorectal cancers that have not responded to standard treatments. The drug works by blocking a specific protein (PKC epsilon)…

This early-phase trial tests a new cell therapy called NK521 for people with advanced liver cancer (hepatocellular carcinoma) or ovarian cancer that has not responded to standard treatments. NK521 are natural killer (NK) cells that have been gene-edited to remove three proteins t…

This study tests an experimental drug (PD-1/IL-2 bispecific antibody) given before a second surgery in 30 adults whose liver cancer returned early after initial curative surgery. The goal is to see if the drug can shrink or kill more cancer cells before the operation, potentially…

This long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical be…

This phase 2 trial tests two oral drugs, lenvatinib and regorafenib, in 146 adults with advanced liver cancer that cannot be surgically removed and has worsened after initial immunotherapy. The study has two parts: one for patients with better liver function and one for those wit…

This early-stage trial tests a new drug called CRPA1A2, which helps the body's immune cells attack cancer cells. It is for people with certain advanced solid tumors (like lung, esophagus, head and neck, or liver cancer) that have not responded to other treatments. The study will …

This phase 2 trial tests a combination of low-dose bevacizumab (a blood vessel growth blocker) and adebrelimab (an immunotherapy) along with two liver-directed procedures (TACE and HAIC) as a first treatment for people with unresectable hepatocellular carcinoma, a type of liver c…

This study tests whether adding Babao Dan Capsule (a traditional Chinese medicine) to standard antiviral treatment can lower the chance of developing liver cancer in people with hepatitis B-related cirrhosis who are at high risk. About 1,034 adults aged 18-65 with a specific TCM …

This early-phase trial will test a new type of cell therapy called Meta10-GPC3 CAR-T in 27 people with advanced liver cancer that cannot be surgically removed. The treatment involves taking a patient's own immune cells, modifying them to recognize and attack liver cancer cells, a…

This study looks at whether starting denosumab early, along with a standard immunotherapy, can prevent bone problems like fractures or spinal cord compression in people with liver cancer that has spread to the bones. About 50 adults with liver cancer and bone metastases will be r…

This study looks at whether surgically removing the main liver tumor, followed by standard immune-based drug therapy, can help people with liver cancer that has spread to other organs live longer. About 280 adults with resectable liver tumors and at least one metastasis will be r…

This phase 3 trial tests whether adding targeted radiation or other local treatments to standard drug therapy can help people with liver cancer that has spread to a few spots outside the liver. All 400 participants first receive a combination of the immunotherapy sintilimab and t…

This phase 2 trial tests a combination of two drugs (Benmelstobart and Anlotinib) plus targeted radiation (SBRT) in 29 adults with liver cancer that has spread to a few other spots and no longer responds to first-line treatment. The goal is to see if this triple therapy can slow …

This study tests whether adding a traditional Chinese medicine called Biejia-Ruangan compound to standard antiviral therapy can lower the chance of developing liver cancer in people with hepatitis B-related cirrhosis. About 1,034 high-risk adults (based on a special score) will b…

This Phase 2 trial tests whether adding personalized radiotherapy (PULSAR) and fecal microbiota transplants (FMT) to standard targeted-immunotherapy can reverse resistance in advanced liver cancer. About 64 patients whose cancer stopped responding to first-line treatment will be …

This study tests a new combination of drugs (SH006 plus chemotherapy) against the standard drug regorafenib in 120 people with advanced liver cancer that has not responded to immunotherapy. The goal is to see if the new combo can slow cancer growth or improve survival. Participan…

This phase 3 trial compares two treatments for small liver cancer (tumors 5 cm or smaller): surgery to remove the tumor or a precise, high-dose radiation therapy called SBRT. About 312 adults with a single liver tumor will be randomly assigned to one of the two treatments. The st…

This phase II trial tests a personalized approach for people with advanced liver cancer that cannot be removed by surgery. Researchers will classify each patient's tumor by its fatty acid degradation (FAD) subtype and assign either a drug combination (camrelizumab plus apatinib) …

This phase II trial tests whether combining a liver-directed procedure (TACE) with an immunotherapy drug (QL1706) before surgery, followed by more immunotherapy after surgery, can help patients with liver cancer that is too large or numerous for standard transplant criteria. The …

This study compares two antiviral strategies—one using a single drug (TAF) and the other starting with two drugs (entecavir plus TAF) then switching to TAF alone—in 120 people with advanced hepatitis B-related liver cancer who are also receiving immunotherapy. The main goal is to…

This Phase 2 trial tests BB102, a targeted drug that blocks a protein called FGFR4, in 60 adults with advanced liver cancer that has not responded to standard treatments. Participants must have a specific genetic marker (FGF19 overexpression). The study will measure how well the …

This study tests a procedure called irreversible electroporation (IRE), which uses short electrical pulses to kill liver cancer cells while leaving nearby healthy tissue unharmed. It is for people with early-stage liver cancer (HCC) who have good liver function. The goal is to se…

This phase 2 trial is testing a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (lenvatinib), and a procedure that blocks the tumor's blood supply (TACE) in 41 people with advanced liver cancer. The goal is to see if this mix can keep the…

This phase 3 trial tests whether adding an experimental drug (TPST-1120) to standard immunotherapy and anti-angiogenic therapy helps people with advanced liver cancer live longer. About 740 adults whose cancer cannot be surgically removed or has spread will be randomly assigned t…

This phase 2 trial tests the drug cabozantinib in 60 adults with advanced liver cancer that worsened after first-line immunotherapy. The goal is to see if cabozantinib can stop or slow tumor growth for at least 6 months. Researchers will also look for blood and tissue markers tha…

This study tests a new imaging method called 68Ga-NYM207 PET/CT to see if it can safely and accurately detect liver cancer (hepatocellular carcinoma). About 100 adults with suspected or known liver cancer will receive the scan. The goal is to improve how doctors find and monitor …

This study is testing a new blood test that looks for specific DNA changes (methylation) to monitor if liver cancer comes back after treatment. Researchers will enroll 162 adults with liver cancer who have had surgery, transplant, ablation, or chemoembolization. The test's accura…

This Phase 2 trial tests whether a drug called nanocrystalline megestrol acetate can help people with advanced liver cancer who are losing weight and appetite. About 88 patients will receive either the drug or a placebo for 12 weeks while also getting standard cancer therapy. The…

This study tests whether ondansetron, a drug typically used for nausea, can lower the risk and severity of side effects from immunotherapy in people with liver cancer. About 134 patients will receive ondansetron alongside their standard cancer treatment. The goal is to see if thi…

This observational study will use bedside ultrasound to measure the diaphragm—the main breathing muscle—in 120 adults with liver cirrhosis and compare them to healthy volunteers. Researchers want to see if cirrhosis weakens the diaphragm and if removing fluid from the belly impro…

This study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …

This study looks back at data from 562 people who received a liver transplant for liver cancer (hepatocellular carcinoma) at hospitals in France, Canada, and Belgium. The goal is to create a better scoring system that considers tumor shrinkage before transplant, cancer growth whi…

This study will test whether an artificial intelligence (AI) model can help doctors decide between surgery and microwave ablation for people with early-stage liver cancer. The AI will analyze images from contrast-enhanced ultrasound and MRI scans to predict the risk of cancer ret…

This study looks at whether blood tests can predict how well liver cancer responds to a standard treatment called TACE. Researchers will collect blood samples from 60 adults with liver cancer before and after TACE, then compare the results with CT or MRI scans. The goal is to see…

This study will test whether measuring liver tumor volume with CT scans can better assess how well two common treatments—TACE and microwave ablation—are working. Researchers will enroll 66 adults with liver cancer who cannot have surgery. The goal is to improve how doctors track …

This study will analyze data from 2000 liver cancer patients to see how well interventional therapy combined with systemic drugs (like targeted therapy and immunotherapy) works in real life. Researchers will look at differences in outcomes and side effects, and use machine learni…